Sayeef Mirza, MD, MPH

Dr. Mirza’s clinical and research interests involve optimizing stem cell transplantation and cellular therapies for both hematologic malignancies and non-hematologic conditions. He is also interested in immune reconstitution and regulating the immune system to maximize long-term clinical outcomes. He looks forward to synthesizing a career in clinical investigation and translational research. He is spearheading an effort to offer transplant and CAR-T to patients with non-hematologic and/or autoimmune conditions.

Associations

• Blood and Marrow Transplant and Cellular Immunotherapy
• Molecular Medicine Program

Education & Training

Graduate:

• University of South FloridaMPH

Board Certification:

Fellowship:

• Yale University - Hematology & Medical Oncology

Residency:

• University of South Florida - Internal Medicine

Medical School:

• University of South Florida

Dr. Mirza’s research has involved studying the toxicities associated with hematopoietic stem cell transplantation and cellular therapies using both single institutional experiences and multi-institutional registries.

Clinical Trial 23456
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (CTN 2203)
Condition: Immunotherapy
Intervention: Alkeran (Melphalan); Cellcept (Mycophenolate Mofetil); FK506 (Tacrolimus); Jakafi (Ruxolitinib); Melphalan (); Mycophenolate Mofetil (); Radiotherapy (); Ruxolitinib (); Tacrolimus (); busulfan (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); methotrexate ()
Status: Open

Clinical Trial 23614
A Phase 2, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted NEXTCAR T Cells, in Participants with Active SLE (Including Lupus Nephritis) with Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE)
Condition: Immunotherapy
Intervention: CC-97540 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Hoogland AI, Li X, Hu B, Irizarry-Arroyo N, Welniak T, Rodriguez Y, Jain MD, Oswald LB, Small BJ, Snider JT, Wade SW, Chavez JC, Khimani F, Lazaryan A, Liu HD, Nishihori T, Pinilla-Ibarz J, Shah BD, Pidala JA, Logue J, Booth-Jones M, Mirza AS, Huang J, Locke FL, Jim HSL. Age as a moderator of neurocognitive performance in patients with large B-cell lymphoma treated with axicabtagene ciloleucel. Support Care Cancer. 2026 Sep.34(10). Pubmedid: 42709238. Pmcid: PMC13553681.
• Oluwole OO, Crofford L, Jallouk AP, Lee DW, Gardner R, Piquet AL, Jackson SW, Velarde AM, Meyer E, Knight TE, Seshadri MR, Mirza S, Wacker K, Wilfong E. Chimeric Antigen Receptor T-Cell Therapy in Autoimmune Disorders: An Expert Panel Opinion From the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2026 Sep.32(9):1053.e1-1053.e13. Pubmedid: 42134594.
• Mirza AS, Hosing C, Foss F, Kim S, Moskop A, Oloyede T, Abid MB, Afrough A, Ahmed S, Badar T, Barba P, Bhatt VR, Brown VI, Dahiya S, Deol A, Epperla N, Ganguly S, Grover NS, Hashmi H, Hashmi S, Hematti P, Hildebrandt GC, Hill JM, Hossain NM, Ibrahim U, Johnson PC, Kharfan-Dabaja MA, Krem MM, Lekakis LJ, Maziarz RT, Murthy HS, Riedell PA, Salas MQ, Shouse G, Strouse C, Thakar MS, Turtle CJ, Woolfrey A, Wudhikarn K, Yared JA, Pasquini MC, Gowda L. Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomas. Blood Neoplasia. 2026 May.3(2):100187. Pubmedid: 41867486. Pmcid: PMC12999346.
• Wudhikarn K, Gowda L, Ye Q, Oloyede T, Martens M, Banerjee R, Devarakonda SS, Liu H, Herr MM, Young JH, Jain T, Dias A, Nishihori T, Mirza AS, Ganguly S, Beitinjaneh AM, Aljurf M, Wirk B, Farhadfar N, Efebera YA, Perales MA, Ebens CL, Murthy HS, Hill JA, Dandoy CE, Hong S, Boghdadly ZE, Akhtar OS, Auletta JJ, Huppler AR, Abid MB. Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis. Transplant Cell Ther. 2026 Jun. Pubmedid: 42364732. Pmcid: PMC13382910.
• Ahmed N, Ali A, Kim S, Oloyede T, Bye M, Gowda L, Kamble RT, Mirza AS, Nadiminti KV, Pophali PA, Rodriguez-Bonilla C, Sieg A, Strouse C, Abid MB, Afrough A, Aljurf M, Beitinjaneh AM, Chhabra S, Choe M, Hilal T, Iqbal M, Jain T, Kharfan-Dabaja MA, Modi D, Orti G, Pawarode A, Rao U, Riedell PA, Saad A, Seo S, Balari AS, Wagner JL, Wudhikarn K, Turtle CJ, Phillips CL, Pasquini MC, Ahmed S, Ganguly S, Moskop A. Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma. Transplant Cell Ther. 2026 Jun. Pubmedid: 42341926.
• Ramlal R, Kim J, Thompson Z, Ochoa-Bayona L, Mishra A, Nishihori T, Perez L, Bejanyan N, Castaneda Puglianini O, Faramand R, Mirza S, Khimani F, Lazaryan A, Hansen D, Locke F, Artz A, Sorror M, Pidala J. Single center evaluation of a composite risk assessment model to predict non-relapse mortality following allogeneic hematopoietic cell transplantation (HCT). Bone Marrow Transplant. 2026 Jun.61(6):702-704. Pubmedid: 41951840.
• Pidala JA, Cieri N, Schell MJ, Song X, Shao Y, Cao B, Du D, Thapa R, Betts BC, Janssen W, Cubitt C, Yoder SJ, O'Leary MF, Beato F, Veerapathran A, Menges MA, Burton M, Bejanyan N, Castaneda-Puglianini OA, Elmariah H, Faramand RG, Fernandez HF, Hansen DK, Jain MD, Khimani F, Lazaryan A, Liu HD, Locke FL, Mirza AS, Mishra A, Nieder M, Nishihori T, Ochoa L, Perez LE, Perna F, Ramlal R, Torres NE, Anasetti C. Expanded antigen-specific donor regulatory T cells for GVHD prevention. Blood. 2026 Jun. Pubmedid: 42322116.
• Parker NH, Kim J, Bean M, De Vera MT, Carmella R, Duca A, Corallo S, Delgado LC, Merritt E, McCoy J, Brushwood A, Franca M, Hansen DK, Castaneda-Puglianini O, Lazaryan A, Chavez J, Nishihori T, Shah B, Faramand R, Mirza AS, Akhtar O, Peres LC, Figura NB, Jhaveri K, Oswald LB, Jim HSL, Locke FL, Jain M, Freeman CL. Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary Outcomes. Transplant Cell Ther. 2026 Jun. Pubmedid: 42315024.
• Saha A, Whiting J, Mohty R, Flores K, Kim J, Nishihori T, Chavez J, Gaballa S, Khimani F, Liu H, Shah B, Dam M, Jaffer M, Mokhtari S, Ghalehsari N, Elmariah H, Bachmeier C, Guevara JA, Jim H, Mirza S, Segal BH, Hansen DK, Bejanyan N, Perna F, Faramand R, Jain M, Locke F, Lazaryan A. A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-cell lymphoma. Bone Marrow Transplant. 2026 Jul. Pubmedid: 42469394.
• Pidala JA, Kim J, Laborde J, Knott S, Mogili K, Zinn J, Monroe AR, Faramand R, Ramlal R, Khimani F, Hansen DK, Torres Luna NE, Jain MD, Perez LE, Mishra A, Ghalehsari N, Castaneda-Puglianini OA, Alsina M, Perna F, Nieder M, Mirza AS, Liu HD, Nishihori T, Ali A, Chellapandian D, Locke FL, Bejanyan N, Anasetti C, Lazaryan A. Chronic graft vs. host disease following post-transplant cyclophosphamide (PTCy) based prophylaxis vs. non-PTCy prophylaxis. Blood Adv. 2026 Jul. Pubmedid: 42480215.
• Crombie JL, Ahmed S, Frigault MJ, Hunter BD, Palomba ML, Mirza AS, Lunning MA, Egini O, Odstrcil Bobillo MS, Kallam A, Kambhampati Thiruvengadam S, Lee D, Dahiya S, Hamadani M, Herrera AF, Lee CJ, Patel K, Patel SS, Reagan PM, Shadman M, Bernasconi D, Kim S, Liu FF, Roy D, Pasquini MC, Isufi I. Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma. Blood. 2026 Jul.148(3):348-360. Pubmedid: 41774517.
• Hunter BD, Lunning M, Shadman M, Ahmed S, Abramson JS, Perales MA, Ahmed N, Mirza AS, Isufi I, Frigault MJ, Crombie JL, Miklos DB, Vasconcelos A, Crotta A, Bernasconi D, Roy D, Bleickardt E, Pasquini MC, Kamdar M. CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting. Transplant Cell Ther. 2026 Feb.32(2):171.e1-171.e12. Pubmedid: 41235976. Pmcid: PMC13012614.
• Hansen DK, Dima D, Mian H, Devos J, Brazauskas R, Oloyede T, Afrough A, Ahmed N, Anderson LD, Banerjee R, Berdeja JG, Bidikian A, Dhakal B, Dias A, Efebera Y, Faisal MS, Gowda L, Hashmi H, Mirza AS, Mohan M, Narra R, Rosko AE, Schroeder M, Nishihori T, Landau H, Usmani S, Pasquini MC, Akhtar OS, Sidana S, Patel KK. Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study. Blood Cancer J. 2026 Aug.16(1). Pubmedid: 42675051. Pmcid: PMC13530125.
• Hansen DK, Dima D, Mian H, Devos J, Brazauskas R, Oloyede T, Afrough A, Ahmed N, Anderson L, Banerjee R, Berdeja JG, Bidikian A, Dhakal B, Dias A, Efebera Y, Faisal MS, Gowda L, Hashmi H, Mirza AS, Mohan M, Narra R, Rosko AE, Schroeder M, Nishihori T, Landau H, Usmani S, Pasquini MC, Akhtar OS, Sidana S, Patel KK. Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study. Blood Cancer J. 2026 Apr.16(1). Pubmedid: 41980929. Pmcid: PMC13194909.
• Schmitz J, Gaskill E, Price S, Cao B, Kim J, Baluch A, Klinkova O, Faramand R, Mishra A, Perez L, Khimani F, Lazaryan A, Ochoa-Bayona JL, Liu H, Mirza AS, Nieder M, Anasetti C, Nishihori T, Pidala JA, Bejanyan N, Elmariah H. Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide. Bone Marrow Transplant. 2025 Oct.60(10):1383-1386. Pubmedid: 40617898.
• Sidana S, Ahmed N, Akhtar OS, Brazauskas R, Oloyede T, Bye M, Hansen DK, Ferreri CJ, Freeman CL, Afrough A, Anderson LD, Dhakal B, Dhanda DS, Gowda L, Hashmi H, Harrison MJ, Kitali A, Landau HJ, Mirza AS, Patwardhan P, Qazilbash MH, Usmani SZ, Patel KK, Nishihori T, Ganguly S, Pasquini MC. Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma. Blood. 2025 Jul.146(2):167-177. Pubmedid: 40198886.
• Shouval R, Strouse C, Kim S, Oloyede T, Ahmed S, Awan FT, Luan D, Bachanova V, Badar T, Bar M, Barba P, Beitinjaneh AM, Cashen A, Dholaria B, Elsawy M, Ganguly S, Geethakumari PR, Greenbaum U, Hashmi H, Hill LC, Jain MD, Jain T, Kebriaei P, Kittai AS, Locke FL, Lulla PD, Mead E, McGuirk JP, Mussetti A, Nishihori T, Olson AL, Pennisi M, Perales MA, Riedell PA, Saber W, Mirza AS, Magalhaes-Silverman M, Shpall EJ, Sorror M, Wudhikarn K, Turtle CJ, Moskop A, Pasquini MC. Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma. Transplant Cell Ther. 2025 Jul.31(7):419-433. Pubmedid: 40288610.
• Akhtar OS, Oloyede T, Brazauskas R, Afrough A, Hashmi H, Sidana S, Ahmed N, Bye M, Hansen DK, Ferreri CJ, Dhakal B, Dhanda DS, Harrison MJ, Kitali A, Landau HJ, Mirza AS, Patel J, Patwardhan P, Qazilbash MH, Patel KK, Nishihori T, Ganguly S, Gowda L, Anderson LD, Pasquini MC, Usmani SZ, Freeman CL. Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study. Blood Adv. 2025 Apr.9(7):1587-1592. Pubmedid: 39786391. Pmcid: PMC11986210.
• Handley G, Yepes A, Eliassen E, Dominguez G, Pasikhova Y, Klinkova O, Baluch A, Febres-Aldana AJ, Alsina M, Elmariah H, Khimani F, Hansen DK, Freeman CL, Jain MD, Locke F, Lazaryan A, Liu HD, Mishra A, Mirza AS, Nishihori T, Ochoa L, Perez L, Pidala J, Puglianini OC, Nieder M, Perna F, Kim J, Bejanyan N, Faramand R. Outcomes of Haploidentical Stem Cell Transplant Recipients With HHV-6B Reactivation. Open Forum Infect Dis. 2024 Oct.11(10):ofae564. Pubmedid: 39411216. Pmcid: PMC11475747.
• Locke FL, Siddiqi T, Jacobson CA, Ghobadi A, Ahmed S, Miklos DB, Perales MA, Munoz J, Fingrut WB, Pennisi M, Gauthier J, Shadman M, Gowda L, Mirza AS, Abid MB, Hong S, Majhail NS, Kharfan-Dabaja MA, Khurana A, Badar T, Lin Y, Bennani NN, Herr MM, Hu ZH, Wang H, Baer A, Baro E, Miao H, Spooner C, Xu H, Pasquini MC. Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity. Blood. 2024 Jun.143(26):2722-2734. Pubmedid: 38635762. Pmcid: PMC11251200.
• Mirza AS, Lazaryan A. Minimalist approach to conditioning intensity for allogeneic transplantation of patients with non-Hodgkin Lymphoma: if less is more, than how low do we go?. Transplant Cell Ther. 2024 Jan.30(1):11-13. Pubmedid: 38185504.
• Leveille E, Chan LN, Mirza AS, Kume K, Müschen M. SYK and ZAP70 kinases in autoimmunity and lymphoid malignancies. Cell Signal. 2022 Jun.94:110331. Pubmedid: 35398488.
• MacDonald M, Mirza AS, Mhaskar R, Ewing A, Chen L, Robinson K, Lu Y, Ayoubi N, Gonzalez E, Guerra L, Roetzheim R, Woodard L, Pabbathi S. Preventative Cancer Screening Rates Among Uninsured Patients in Free Clinics: A Retrospective Cohort Study of Cancer Survivors and Non-cancer Survivors. Cancer Control. 2022 Jan.29. Pubmedid: 35245986. Pmcid: PMC8902193.
• Mirza AS, Tandon A, Jenneman D, Cao S, Brimer T, Kumar A, Kidd M, Khimani F, Faramand R, Mishra A, Liu H, Nishihori T, Perez L, Lazaryan A, Bejanyan N, Nieder M, Pidala J, Elmariah H. Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2022 Apr.28(4):185.e1-185.e7. Pubmedid: 35017119.
• Nguyen M, Dyjak P, MacDonald M, Vivar J, Shah S, Swanson J, Pruitt Z, Mirza AS, Mhaskar R. Treatment of Pharyngitis in Uninsured Patients: A Multicenter Study of Free Clinics. Cureus. 2021 Oct.13(10):e18564. Pubmedid: 34760411. Pmcid: PMC8571809.
• Mushtaq S, Prabakaran S, Elharake M, Mirza S, Ravindran A, Faramand R, Sokol L. Primary Effusion Lymphoma: Small Bowel Recurrence After Stem Cell Transplant. ACG Case Rep J. 2021 Nov.8(11):e00698. Pubmedid: 34820467. Pmcid: PMC8608261.
• Mirza AS, Kumar A, Hashmi H, Garcia F, Logothetis CN, Darwin A, Faramand R, Reid K, Bachmeier C, Chavez JC, Shah B, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, Nishihori T, Locke FL, Jain MD. Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma. Transplant Cell Ther. 2021 Mar.27(3):242.e1-242.e6. Pubmedid: 33781520.
• Rahman S, Mirza AS, Wathington D, Green S, Mayers Y, Iranmanesh E, Woodard L. Chronic disease and socioeconomic factors among uninsured patients: A retrospective study. Chronic Illn. 2021 Mar.17(1):53-66. Pubmedid: 30782011.
• Mathews AT, Mirza AS, Bohra C, Mathews AG, Ritucci-Chinni P, L Weber J, W Bulkeley W, Siddique M, Whitaker D, Bowerman R. Diagnosing Cardiac Amyloidosis: From Heart Failure to Electrical Storm. Case Rep Med. 2021 Jun.2021:3293728. Pubmedid: 34239572. Pmcid: PMC8238623.
• Rivera Rivero B, Makarova A, Sidig D, Niazi S, Abddelgader R, Mirza S, Joud H, Urfi M, Ahmed A, Jureyda O, Khan F, Swanson J, Siddique M, Weare-Regales N, Mirza AS. Nutritional Literacy Among Uninsured Patients With Diabetes Mellitus: A Free Clinic Study. Cureus. 2021 Jul.13(7):e16355. Pubmedid: 34414041. Pmcid: PMC8364779.
• Joud H, Mohamed E, Mirza S, Tabbaa H, Tabbaa M, Khan F, Ayoubi N, MacDonald M, Woodard L, Oxner A, Guerra L, Bakour C, Mirza AS. Prevalence and management of diabetes among the uninsured: A multicenter study in Tampa Bay, FL. Diabetes Res Clin Pract. 2021 Jan.171:108560. Pubmedid: 33271229.
• Song EY, Swanson J, Patel A, MacDonald M, Aponte A, Ayoubi N, Guerra L, Gonzalez E, Mhaskar R, Mirza AS. Colorectal Cancer Risk Factors and Screening Among the Uninsured of Tampa Bay: A Free Clinic Study. Prev Chronic Dis. 2021 Feb.18:E16. Pubmedid: 33630731. Pmcid: PMC7938966.
• Bewersdorf JP, Allen C, Mirza AS, Grimshaw AA, Giri S, Podoltsev NA, Gowda L, Cho C, Tallman MS, Zeidan AM, Stahl M. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis. Transplant Cell Ther. 2021 Dec.27(12):997.e1-997.e11. Pubmedid: 34551341. Pmcid: PMC9533376.
• Hashmi H, Mirza AS, Darwin A, Logothetis C, Garcia F, Kommalapati A, Mhaskar RS, Bachmeier C, Chavez JC, Shah B, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, Locke FL, Nishihori T, Jain MD. Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. Blood Adv. 2020 Sep.4(17):4086-4090. Pubmedid: 32877523. Pmcid: PMC7479945.
• MacDonald MR, Zarriello S, Swanson J, Ayoubi N, Mhaskar R, Mirza AS. Secondary prevention among uninsured stroke patients: A free clinic study. SAGE Open Med. 2020 Oct.8. Pubmedid: 33110604. Pmcid: PMC7564623.
• Liu N, Mathews A, Swanson J, Mhaskar R, Mathews A, Ayoubi N, Mirza AS. Aspirin use for cardiovascular disease prevention in the uninsured population. SAGE Open Med. 2020 Jun.8. Pubmedid: 32647578. Pmcid: PMC7328214.
• MacDonald M, Shah S, Swanson J, Song E, Ahsan T, Pabbathi S, Mhaskar R, Mirza AS. Substance Use in Uninsured Cancer Survivors: A Multicenter Cross-Sectional Study of Free Clinics. Cureus. 2020 Aug.12(8):e10083. Pubmedid: 33005507. Pmcid: PMC7522175.
• Mirza AS, Horna P, Teer JK, Song J, Akabari R, Hussaini M, Sokol L. New Insights Into the Complex Mutational Landscape of Sézary Syndrome. Front Oncol. 2020 Apr.10:514. Pubmedid: 32373524. Pmcid: PMC7186303.
• Mirza AS, Chen L, Amirzadeh S, Majethia S, Joppen J, Mirza S, Mhaskar R, Jaglal M, Ashraf N. Health disparities and chronic disease associated with anemia in free clinics: A retrospective study of uninsured patients in Tampa Bay. Postgrad Med. 2019 Sep.131(8):612-618. Pubmedid: 31524033.
• Mirza AS, Dholaria BR, Hussaini M, Mushtaq S, Horna P, Ravindran A, Kumar A, Ayala E, Kharfan-Dabaja MA, Bello C, Chavez JC, Sokol L. High-dose Therapy and Autologous Hematopoietic Cell Transplantation as Consolidation Treatment for Primary Effusion Lymphoma. Clin Lymphoma Myeloma Leuk. 2019 Sep.19(9):e513-e520. Pubmedid: 31253594.
• Mirza AS, Yun S, Ali NA, Shin H, O'Neil JL, Elharake M, Schwartz D, Robinson K, Nowell E, Engle G, Badat I, Brimer T, Kuc A, Sequeira A, Mirza S, Sikaria D, Vera JD, Hackney N, Abusrur S, Jesurajan J, Kuang J, Patel S, Khalil S, Bhaskar S, Beard A, Abuelenen T, Ratnasamy K, Visweshwar N, Komrokji R, Jaglal M. Validation of the Khorana score in acute myeloid leukemia patients: a single-institution experience. Thromb J. 2019 Jul.17:13. Pubmedid: 31303864. Pmcid: PMC6604148.
• Ayoubi N, Mirza AS, Swanson J, Hamoui R, Mhaskar R. Dermatologic care of uninsured patients managed at free clinics. J Am Acad Dermatol. 2019 Aug.81(2):433-437. Pubmedid: 30878564.
• Pribish A, Khalil N, Mhaskar R, Woodard L, Mirza AS. Chronic Disease Burden of the Homeless: A Descriptive Study of Student-Run Free Clinics in Tampa, Florida. J Community Health. 2019 Apr.44(2):249-255. Pubmedid: 30324539.
• Mirza AS, Pabbathi S, Lu Y, Ayoubi N, Ewing A, Jaglal M, Roetzheim R. Comorbidities, risk, and socioeconomic factors of uninsured cancer survivors. Medicine. 2018 Nov.97(47):e13121. Pubmedid: 30461610. Pmcid: PMC6393034.
• Hussaini MO, Mirza AS, Komrokji R, Lancet J, Padron E, Song J. Genetic Landscape of Acute Myeloid Leukemia Interrogated by Next-generation Sequencing: A Large Cancer Center Experience. Cancer Genomics Proteomics. 2018 Mar.15(2):121-126. Pubmedid: 29496691. Pmcid: PMC5892606.
• Strati P, Tang G, Duose DY, Mallampati S, Luthra R, Patel KP, Hussaini M, Mirza AS, Komrokji RS, Oh S, Mascarenhas J, Najfeld V, Subbiah V, Kantarjian H, Garcia-Manero G, Verstovsek S, Daver N. Myeloid/lymphoid neoplasms with FGFR1 rearrangement. Leuk Lymphoma. 2018 Jul.59(7):1672-1676. Pubmedid: 29119847.
• Markow M, Mirza AS, Perez L, Shao H, Horna P, Anasetti C, Sokol L, Hussaini MO. Transformation of T-Cell Acute Lymphoblastic Lymphoma to Peripheral T-Cell Lymphoma: A Report of Two Cases. Case Rep Hematol. 2018 Feb.2018:9191582. Pubmedid: 29682368. Pmcid: PMC5850893.
• Rahman S, Mirza AS, Stenback J, Green S, Mayers Y, Iranmanesh E, Pribish A, Islam S, Woodard L. Burden of Chronic Conditions among Patients from Free Clinics: A Retrospective Chart Review of 2015. J Health Care Poor Underserved. 2018 Dec.29(3):1011-1026. Pubmedid: 30122680.
• Mirza AS, Rodriguez VV. Cave diving for a diagnosis: Disseminated histoplasmosis in the immunocompromised. IDCases. 2018 Apr.12:92-94. Pubmedid: 29942759. Pmcid: PMC6010963.
• Mirza AS, Verma S, Fu L, Bassil C. Thrombotic Microangiopathy With Granulomatosis Interstitial Nephritis in an Allogenic Bone Marrow Transplant Patient: A Case Report and Review of the Literature. J Hematol (Brossard). 2017 Sep.6(2-3):52-58. Pubmedid: 32300393. Pmcid: PMC7155822.
• Mirza S, Hill E, Ludlow SP, Nanjappa S. Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome. Melanoma Res. 2017 Jun.27(3):271-273. Pubmedid: 28146044.
• Mirza AS, Lancet JE, Sweet K, Padron E, Pinilla-Ibarz J, Nardelli L, Cubitt C, List AF, Komrokji RS. A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2017 Dec.17(12):902-907. Pubmedid: 29030092.
• Hussaini M, Yeung C, Zhu X, Mirza AS, Pfeifer J, Hassan A. PRDM1 expression levels in marginal zone lymphoma and lymphoplasmacytic lymphoma. Int J Clin Exp Pathol. 2017 Aug.10(8):8610-8618. Pubmedid: 31966717. Pmcid: PMC6965379.
• Fang B, Hoffman MA, Mirza AS, Mishall KM, Li J, Peterman SM, Smalley KS, Shain KH, Weinberger PM, Wu J, Rix U, Haura EB, Koomen JM. Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides. Methods. 2015 Jun.81:41-49. Pubmedid: 25782629. Pmcid: PMC4460980.

• Title: A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity
  Award Number: N/A
  Sponsor: Medical College of Virginia Foundation (MCVF)
  Mirza, A. (PD/PI), Pidala, J. ()